Newsfeeds - Spark Newswire

4 minute read

Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday’s Mid-Day Session

Today, 3:18 PM

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.

ARDS

2 minute read

Analyst Ratings

What 5 Analyst Ratings Have To Say About Sage Therapeutics

By Benzinga Insights

Today, 3:18 PM

Over the past 3 months, 5 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts…

SAGE

1 minute read

FDA
News

Sage Therapeutics & Biogen Reveal FDA Does Not Currently Plan To Convene Advisory Committee Meeting To Discuss NDA For Zuranolone In Treatment Of Major Depressive Disorder & Postpartum Depression

By Benzinga Newsdesk

Today, 3:18 PM

Sage Therapeutics, and Biogen announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the

BIIB

1 minute read

Mizuho Maintains Neutral on Sage Therapeutics, Raises Price Target to $45

By Benzinga Newsdesk

Today, 3:18 PM

Mizuho analyst Vamil Divan maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and raises the price target from $37 to $45.

SAGE

1 minute read

Needham Reiterates Buy on Sage Therapeutics, Maintains $70 Price Target

By Benzinga Newsdesk

Today, 3:18 PM

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Buy and maintains $70 price target.

SAGE

1 minute read

Sage Therapeutics Q4 EPS $(2.47) Misses $(2.39) Estimate, Sales $2.87M Beat $1.94M Estimate

By Benzinga Newsdesk

Today, 3:18 PM

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.47) per share which missed the analyst consensus estimate of $(2.39) by 3.35 percent. This is a 16.51 percent decrease over losses of $(2.12) per share

SAGE

9 minute read

Earnings

Earnings Scheduled For February 16, 2023

By Benzinga Insights

Today, 3:18 PM

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.

AEL

2 minute read

Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’

By Vandana Singh

Today, 3:18 PM

The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…

BIIB

1 minute read

Sage Therapeutics to Provide Update on 2023 Key Milestones at 41st Annual J.P. Morgan Healthcare Conference

By Charles Gross

Today, 3:18 PM

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer, Barry Greene, will discuss the Company's progress in developing a leading brain health pipeline at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

SAGE